Table 6.
Healthcare resource outcomes of ceftaroline fosamil treatment
| Outcome measure | Clinical response to ceftaroline fosamila | |
|---|---|---|
| Response (n = 151) | No response (n = 34) | |
| Length of stay, days, mean (SD) | ||
| Hospital | 18.3 (17.5) | 24.1 (20.9) |
| ICU | 3.6 (6.7) | 9.2 (13.2) |
| Hospital costs, USD, mean (SD) | ||
| Standard hospitalb | 8449.3 (12 581.6) | 12 559.1 (13 908.4) |
| Advanced-level hospitalc | 23 031.7 (29 917.1) | 35 961.6 (37 359.3) |
USD, US dollars.
aClinical response defined as demonstrating clinical stability (defined according to the IDSA guidelines20 as temperature of ≤37.8°C, heart rate of ≤100 beats/min, respiratory rate of ≤24 breaths/min, systolic blood pressure of ≥90 mmHg, oxygen saturation of ≥90%, and confusion/disorientation recorded as absent) and clinical improvement [defined as improvement of at least one of four symptoms present at baseline (i.e. cough, dyspnoea, pleuritic chest pain or sputum production) with worsening of none].
bStandard hospital cost: total time in hospital multiplied by per diem rate of standard hospital general ward.
cAdvanced hospital cost: total time in hospital multiplied by per diem rate of hospitals providing the highest level of medical services.